Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.57 |
| ▸ | GSK3B | P49841 | 17/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.57 |
| ▸ | SRC | P12931 | 10/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205515 | 0.89 | AURKA (0.72) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2203175 | 0.88 | AURKA (0.56) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2206175 | 0.87 | AURKA (0.55) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2205907 | 0.86 | AURKA (0.67) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2203023 | 0.86 | AURKA (0.71) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2203222 | 0.86 | AURKA (0.73) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2204682 | 0.84 | AURKA (0.73) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2205463 | 0.84 | AURKA (0.52) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2204915 | 0.83 | AURKA (0.71) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL2206767 | 0.82 | AURKA (0.60) | AURKAGSK3BAURKBSRCAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4160392-B2 | — | — | 2008-10-01 | — | — | JP | claimed |
| CN-100408573-C | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2008-08-06 | — | — | CN | claimed |
| EP-1345926-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| JP-2004517926-A | — | — | 2004-06-17 | — | — | JP | claimed |
| CN-1486311-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | claimed |
| US-6653301-B2 | For therapy of cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-25 | — | — | US | claimed |
| EP-1345926-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030078275-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | claimed |
| WO-2002059111-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| US-7982037-B2 | (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078275-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885AURKB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.